On October 19, 2026 TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA-based therapeutics for the treatment of high risk and advanced cancers, reported that a poster featuring TTX-MC138, the Company’s lead therapeutic candidate, has been accepted and will be presented at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2026 in Madrid, Spain, on October 23, 2026.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The poster, titled "Phase 1a Clinical Trial of TTX-MC138, a First-in-Class AntagomiR against Advanced Solid Tumors," will highlight the most recent clinical update from the Phase 1a evaluation of TTX-MC138 in patients with advanced solid tumors. TTX-MC138 is an investigational therapeutic designed to target miR-10b, a microRNA associated with metastatic disease progression.
"We are honored to have the opportunity to present our most recent TTX-MC138 clinical results at ESMO (Free ESMO Whitepaper), one of the world’s leading oncology meetings," said Zdravka Medarova PhD, Chief Scientific Officer of TransCode. "This poster provides an opportunity to share our clinical experience with TTX-MC138 with the global oncology community and highlight our continued development of this novel therapeutic approach."
Presentation Details
Title: Phase 1a Clinical Trial of TTX-MC138, a First-in-Class AntagomiR against Advanced Solid Tumors
Category: Developmental Therapeutics
Poster: Poster 1025P
Date: October 23, 2026
Location: ESMO (Free ESMO Whitepaper) Congress 2026, Madrid, Spain
The ESMO (Free ESMO Whitepaper) Congress 2026 is being held in Madrid, Spain, from October 23 through October 27, 2026.
(Press release, TransCode Therapeutics, OCT 19, 2026, View Source [SID1234673582])